InnoCare Pharma Limited (stock code: 9969) reported its unaudited third-quarter 2025 results, highlighting total operating revenue of RMB1.12 billion from January to September, a 59.85% increase compared with the same period last year. The rise was primarily driven by continued sales growth of the core product orelabrutinib and upfront payments from an exclusive license agreement. Gross profit margin reached 88.8% in the first nine months, an increase of 2.8 percentage points year-on-year.

Sales revenue of orelabrutinib reached RMB1.01 billion during the first three quarters, marking a 45.77% increase year-on-year. Orelabrutinib’s newest approved indication covers first-line treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The product is already listed for multiple indications in the National Reimbursement Drug List.

During the first nine months of 2025, InnoCare Pharma Limited recorded a net loss of RMB72 million, a 74.78% reduction compared to the same period in 2024, reflecting stronger performance in top-line results. As of 30 September 2025, the Company reported cash and related accounts of approximately RMB7.759 billion.

Additionally, the board announced changes in the Nomination Committee effective 13 November 2025. Independent Non-Executive Director Prof. Kunliang Guan joined the Nomination Committee, while Independent Non-Executive Director Ms. Lan Hu stepped down from the committee. The change aligns with updated corporate governance requirements and aims to increase committee diversity and enhance overall governance practices.